Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
atopic dermatitis
Pharma
FDA approves Galderma's prurigo nodularis treatment Nemluvio
Swiss skincare specialist Galderma has earned FDA approval for Nemluvio to treat the debilitating and itchy skin disease prurigo nodularis.
Kevin Dunleavy
Aug 13, 2024 10:37am
Lilly adds skin disease health equity to ‘Get Better’ campaign
Jul 1, 2024 10:23am
Incyte's JAK cream Opzelura slows while Leo competition looms
May 3, 2024 10:53am
Head-to-head, it's AbbVie's Rinvoq over Regeneron's Dupixent
Apr 26, 2024 7:39am
Dermavant's Vtama excels in another trial in atopic dermatitis
Jan 11, 2024 10:46am
Dermavant CEO draws Botox comparison to instill Vtama confidence
Nov 28, 2023 4:10pm
